Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.

Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, ...

The about-$1 billion deal could come imminently.

Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...

Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be ...

Aktis Oncology Inc. shares jumped 24 percent in their trading debut after the clinical-stage biotechnology company raised ...

Schrödinger (SDGR) stock and Revvity (RVTY stock are in focus as firms join Eli Lilly (LLY) to integrate their software with ...

The project was secured by a Jobs, Energy, Technology and Innovation Act (JETI) tax agreement, which includes a school tax ...

Schrödinger (SDGR) stock is in focus as the firm teams up with Eli Lilly (LLY) to integrate its LiveDesign software with ...

An approval of Lilly's pill, along with its current strength in the weight loss market, could equal revenue growth well into ...

The big lure for Eli Lilly to build a $6.5 billion pharmaceuticals plant in Houston is now official — and details are out on ...

BRANCHBURG – Korean pharmaceutical firm Celltrion has launched operations at the former Eli Lilly facilities on Imclone Drive ...